Dongbang Medical Co., Ltd.
KKRX:2405505,540.00
KRW
-30.00
(-0.54%)
ISIN
KR7240550004
Return %
Stock
S&P 500
1Y
-44.66
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Geun-Sik Kim
- Full Time Employees
- 305
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Woorim W-CITY Boryeong-si SL South Korea 13486
- IPO Date
- Feb 13, 2025
- Website
- dongbangmedical.co.kr
- Similar Companies
- Business
- DongBang Medical Co Ltd (240550.KQ) manufactures and sells aesthetic and oriental medical devices in South Korea. The company produces hyaluronic acid (HA) dermal fillers including ELASTY GRAND, ELASTY DEEP PLUS, ELASTY G PLUS, ELASTY D PLUS and ELASTY F PLUS for facial wrinkle improvement and volume recovery; polydioxanone (PDO) threads such as ELASTY LINE, ELASTY MESHFILL, ELASTY-V BARB, ELASTY-V UP, ELASTY-V SCREW and ELASTY-V MONO for skin lifting and rejuvenation; cannulas, needles and syringes; sterile acupuncture needles for single use; air extraction cupping devices; hand acupuncture products; and cosmetics including HA masks, Beta-Glucan masks, FILL US patches, AG Solution serums and creams, AT Solution lotions and cleansers, AC Solution products, and hair scalp shampoos, treatments and tonics. DongBang Medical operates through cosmetic medical devices and oriental medical devices segments, targeting aesthetic clinics, hospitals and healthcare professionals; it exports to approximately 50 countries across North America, South America, Europe, Asia and the Middle East. Founded in 1985 and headquartered in Seongnam-si, South Korea, the company completed a Kosdaq initial public offering in February 2025 raising KRW 31.5-32.4 billion at KRW 10,500 per share with a 106-910 to 1 subscription rate; it also established a joint hyaluronic acid filler production facility in China's Zhejiang province with Xinyang Group, which holds 33% of the local beauty market, targeting monthly output of 100,000 units pending NMPA approval to enhance price competitiveness and distribution.